News – Page 1124 – Endpoints News

Vertex shares surge as its cystic fibrosis combo proves marginally positive, but payers may not be so impressed

9 years ago

Vertex is reorganizing and consolidating R&D, shuttering a site in Canada

9 years ago

Regeneron and Sanofi land the big one, winning FDA approval for their megablockbuster hopeful Dupixent

9 years ago

Papiernik named chairman at Sofinnova Partners; Cara shares surge on positive data for uremic pruritus

9 years ago

Take that Editas: CRISPR Therapeutics and colleagues win a European round in the IP tug-of-war over gene editing tech

9 years ago

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

9 years ago

A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0

9 years ago

Bristol-Myers partners with Parker Institute, CRI on a next-gen twist on translational R&D

9 years ago

Swiss antibody shop Numab strikes an immuno-oncology discovery deal with Japan’s Ono

9 years ago

FDA OKs Tesaro’s niraparib for ovarian cancer, handing the biotech a big win on the label

9 years ago

Pumped by an early glimpse of efficacy, Newron charts a pivotal course for schizophrenia drug

9 years ago

Erytech shares soar on positive results for PhIIb pancreatic cancer trial; ArQule’s tivantinib fails yet again in ...

9 years ago

Amgen triggers yet another revamp, moving researchers to two big hubs

9 years ago

A Foamix acne drug PhIII bombs, sending shares into a tailspin

9 years ago

Allergan scores a PhIII win with an acne drug now headed to the FDA

9 years ago

Novartis-backed Ionis subsidiary Akcea maps a $100M IPO as it steers a lead drug to regulators

9 years ago

Ex-Baxalta CEO Ludwig Hantson gets the top job at a troubled Alexion

9 years ago

Novartis research leader takes the helm at Forty Seven, a CIRM-backed fledgling already deep in the clinic

9 years ago

Put away the flamethrower Mr. President. We come in peace and prosperity.

9 years ago

Eli Lilly unveils an $850M makeover as Trump pounds the table for new US jobs, manufacturing

9 years ago

FDA starts the priority review clock for Symbiomix; Cornerstone gets a green light on pivotal studies

9 years ago

That $95M Merck gamble to acquire cCAM? It didn’t pay off.

9 years ago

Xenon’s lead in-house drug flops in a mid-stage test and stock plunges lower

9 years ago

Novartis laterals two PhII anti-aging drugs to a PureTech startup, grabbing an equity stake

9 years ago

First page Previous page 1121 1122 112311241125 1126 1127 Next page Last page